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Spread of carbapenemase producers in Enterobacteriaceae is now identified worldwide. 
Three main carbapenemases are reported which belong to three classes of ß-lactamases 
that are KPC, NDM and OXA-48. The main reservoirs of KPC are Klebsiella pneumoniae 
in the USA, Israel, Greece and Italy, of NDM are K. pneumoniae and Escherichia coli in 
the Indian subcontinent, and of OXA-48 are K. pneumoniae and E. coli in North Africa 
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and Turkey. KPC producers remain mostly identified in nosocomial isolates whereas NDM 
and OXA-48 producers are both nosocomial and community-acquired pathogens. Control 
of their spread is still possible in hospital settings and relies on the use of rapid diagnostic 
techniques and strict implemention of hygiene measures. 
 
Although rarely reported a decade ago, carbapenemase-producers in Enterobacteriaceae, they 
are extensively reported nowadays. Different groups of enzymes possessing carbapenemase 
properties have emerged, and are spreading worldwide concomitantly. Some of those 
enzymes hydrolyze carbapenems very efficiently whereas others exhibit weak activity against 
carbapenems. Some include broad-spectrum cephalosporins in their hydrolytic pattern, some 
do not. Some have an activity that may be inhibited (at least partially) by ß-lactamase 
inhibitors (such as clavulanic acid, tazobactam) whereas most are not inhibited by clinically-
available inhibitors. However, those significant differences do not really explain the success 
of the spread of specific enzymes in specific countries or areas [1]. 
 
The main features related to the epidemiology of those enzymes are as follows; 
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i) The first parameter is the primary reservoir. Indeed it is very likely that a specific enzyme 
emerges in a given geographical area where many favorable conditions exist such as high-
density population, poor hygiene, high selective pressure linked to over- and misuse of 
antibiotics. 
 
ii) The second parameter corresponds to the genetics of the carbapenemase gene, since some 
genetic structures are prone to enhance gene plasticity and mobility. Some integron or 
transposon structures and plasmids may indeed favorize horizontal gene transfer. Some 
plasmids possess broad-host range of replication, and can therefore enhance the inter-species 
dissemination, while some others possess narrow-host range. Some plasmids replicate very 
efficiently and are self-conjugative, while others are not self-conjugative or conjugate at very 
low rate. The genetic background of the strain harbouring the carbapenemase gene may also 
play an important role, since the emergence of one gene in a so-called successful clone (being 
for instances more prompt to disseminate from patient to patient, or more prompt to resist on 
dry surfaces) can favorize the initial spread of a carbapenemase through the spread of the 
corresponding bacterial host.  
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iii) The third main parameter corresponds to the level of human population exchanges once a 
reservoir is constituted. If the emergence of a carbapenemase occurs in a geographical area 
where the population is mobile (an important worldwide-located diaspora, tourism, medical 
tourism), then the likelihood to see that resistance determinant emerging worldwide is high. 
 
The spread of carbapenemase genes are explained by those three parameters which are 
combined. Among the four molecular classes according to Ambler classification [2], 
carbapenemases can be found in classes A, B, and D. 
 
The class A carbapenem-hydrolyzing ß-lactamases 
The first carbapenemase (NmcA, Non metallo-carbapenemase of class A) had been identified 
more that 20 years ago in an Enterobacter cloacae isolate. Then the SME enzymes (Serratia 
marcescens enzyme) have been identified in S. marcescens. This family includes 5 variants 
(SME-1 to -5), all being chromosomally-encoded [3] and recovered sporadically throughout 
the United States and Canada [4-6, M. Mulvey, unpublished]. The IMI enzymes (IMIpenem-
hydrolyzing ß-lactamase) have been detected in rare isolates of Enterobacter spp. in USA [7], 
France [8], Croatia [9], Finland [10] and Argentina[11], and more recently a colistin-resistant 
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Enterobacter asburiae isolate was recovered in Ireland [12]. The genes encoding those 
carbapenemases are mostly chromosomally-located and associated to an AmpC type 
regulation (LysR dependant), thus limiting their spread and their expression at a high level. 
However, genes encoding the IMI-2 variant have been found plasmid-located in 
environmental Enterobacter asburiae strains recovered from several US rivers [13] and in a 
single E. cloacae isolate in China [14]. 
 
The first variant of the GES family (for “Guiana Extended-Spectrum ß-lactamase”) 
which is GES-1 which is not a carbapenemase was reported in 2000. The GES family now 
includes 24 variants (http://www.lahey.org/Studies/other.asp#table1) [15]. All the GES 
variants possess the ability to hydrolyze broad-spectrum cephalosporins, but through specific 
amino acid substitutions inside the active site, the extension of their spectrum of activity 
towards carbapenems has been identified for several variants [16]. Among these variants, the 
GES-2, -4, -5, -6, -11, -14, and -18 hydrolyze imipenem efficiently [17]. Although quite rare, 
GES enzymes have been identified worldwide. Among those GES variants for which a 
significant carbapenemase activity is noticed, there are; GES-2 identified in Pseudomonas 
aeruginosa, with one clone being the source of a nosocomial outbreak in South Africa [18]; 
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GES-5 identified in Enterobacteriaceae and P. aeruginosa, being widely reported in South 
America (Brazil) [19,20], and some scattered reports in Turkey [21] and South Korea [22]. 
The GES-11 and -14 variants have been identified in Acinetobacter baumannii only [23], and 
GES-18 identified in P. aeruginosa  and not in Enterobacteriaceae [24]. 
 
Noteworthy, this GES-5 variant possessing a significant carbapenemase activity has 
disseminated quite widely, being found not only in nosocomial settings but also in the 
environment in South America [25], and being the main carbapenem-hydrolyzing GES-type 
enzyme to be identified in Enterobacteriaceae. The high rate of GES-5 producers in South 
America and in particular in Brazil [26] might be a consequence of the occurrence of the non-
carbapenemase GES-1 variant in the same geographical area [27]. It might be speculated that 
a selective pressure with carbapenems selected GES-5 along the years is at the origin of the 
emergence of that carbapenemase.  
 
KPC enzymes (Klebsiella pneumoniae carbapenemases) are currently the most 
clinically-significant enzymes among the class A carbapenemases. Indeed, they are mainly 
identified in K. pneumoniae which is an important nosocomial pathogen, and confer high 
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level of resistance not only to carbapenems but also to most ß-lactams including broad-
spectrum cephalosporins. The first KPC producer (a KPC-2-positive K. pneumoniae) was 
identified in 1996 in the Eastern coast of the USA [28] and then a series of variants have been 
identified, eventhough  KPC-2 remains the most commonly identified variant. There are now 
nineteen KPC variants assigned, all being point-putant derivatives of a common amino acid 
sequence. Within a few years, KPC producers went global and identified in many Gram 
negative species eventhough KPC enzymes are mostly identified in K. pneumoniae [29]. In 
Latin America, KPC producers are endemic in some areas, such as in Colombia, and 
Argentina [29]. Some reports also showed the occurrence of KPC producers in Puerto Rico 
and Mexico [30,31]. 
 
 In Europe, KPC producers have been found almost everywhere, most of the time being 
linked to imports from endemic areas [29]. Those endemic areas in Europe are Greece and 
Italy, and probably Poland where nosocomial outbreaks due to KPC-producing K. 
pneumoniae often occur [32]. In Israel the endemicity of KPC producers has been 
demonstrated through many studies, with lots of nosocomial reports but also, noticeably, with 
some community-occurring cases [29,33]. 
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The extent of the diffusion of KPC in South East Asia is not well known, even if 
China is considered as a country where some areas are facing out endemic situations [29]. In 
India, very few reports on KPC-producing isolates do exist, the most commonly identified 
carbapenemases being NDM and OXA-48-like enzymes (see below). However there are some 
reports showing that KPC producers are occurring in India [34,35]. 
 
Noteworthy, one specific KPC-2- or KPC-3-producing K. pneumoniae clone (ST258) has 
been extensively identified worldwide [36], indicating that it has significantly contributed to 
the spread of this resistance trait. 
 
The class B metallo ß-lactamases (MBL) 
 MBLs which are known to be intrinsic in many environmental and opportunistic 
bacterial species have been identified as acquired enzymes since the early 1990’s, either in 
Pseudomonas or in Enterobacteriaceae [37]. The most common families of acquired class B 
MBLs identified in Enterobacteriaceae include the VIM- and IMP- groups [37], together with 
the emerging NDM group (see below), whereas others such as GIM-1 and KHM-1 are 
sporadic [38,39]. Although reported worldwide, the VIM producers in Enterobacteriaceae are 
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highly prevalent in Southern part of Europe and around the Mediterranean sea (first reported 
in Italy by Cornaglia and colleagues) whereas the IMP producers remain mostly located in 
Asia [37]. 
 
 IMP-type ß-lactamases have been the first acquired MBLs to be identified and 
detected in a series of clinically important Gram-negative bacilli, such as in 
Enterobacteriaceae,  Pseudomonas spp., Acinetobater spp.. In Enterobacteriaceae, IMP-1 
was reported from a Serratia marcescens isolate in Japan in 1991 [40]. So far, 48 IMP 
variants have been assigned and IMP-type carbapenemase producers have spread worldwide. 
However the occurrence of IMP-producing isolates worldwide is much less than that of KPC-, 
VIM-, NDM-, or OXA-48 producers. Wide spread of IMP-type enzymes has been 
demonstrated mainly in Japan, Taiwan, and Eastern China, although single reports have been 
reported in many other countries, being sometimes at the origin of nosocomial outbreaks. 
Another type of MBL corresponds to the VIM-type enzymes (Verona Integron-encoded 
Metallo-ß-lactamase). VIM-1 was first identified in Italy in 1997 [41,42] and then the VIM-2 
variant was reported in France from a P. aeruginosa isolate dating from 1996 [43]. Currently, 
the VIM family includes 41 variants, mainly identified from P. aeruginosa but also from 
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enterobacterial isolates. VIM-2 is actually the most reported MBL worldwide [1], with an 
endemic spread in Southern Europe (Greece, Spain, Italy) and Southeast Asia (South Korea, 
Taiwan), but also found as causing outbreaks in Africa, and in particular in the Ivory Coast 
[44], South Africa [45], Tunisia [46], or some European coutries such as Germany [47], the 
Netherlands [48], and France [49,50]. Those outbreaks are most of the time involving VIM-
producing P. aeruginosa, and rarely enterobacterial species. In Europe, Greece is known to be 
an endemic place for VIM-1-producing Enterobacteriaceae. Many Greek studies report the 
spread of VIM-1-producing K. pneumoniae at a national scale, but this enzyme is also 
identified in E. coli, Citrobacter freundii, Morganella morganii, Serratia spp., and Klebsiella 
oxytoca [51,52]. 
 
 Recently, the KHM-1 ß-lactamase has been identified in Japan from a single C. 
freundii clinical isolate that had been recovered in 1997 [39]. The GIM-1 MBL (that stands 
for “German Imipenemase”) which has been firstly identified from a P. aeruginosa isolate 
from Germany [38] has been then identified in other P. aeruginosa isolates [53] but also in 
Serratia marcescens [54], Enterobacter cloacae [55] and Acinetobacter pittii [56]. Worringly, 
it was recently shown that GIM-1 was identified in many enterobacterial species, including E. 
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coli, C. freundii, and K. oxytoca, always in Germany [53]. The other described acquired 
MBLs include SPM-1 [57], SIM-1 [58], DIM-1 [59], TMB-1 [60], and AIM-1 [61], but they 
have not been identified in Enterobacteriaceae, being either from Pseudomonas spp. or 
Acinetobacter spp 
 
 One of the most most clinically-significant carbapenemase is NDM-1 (New Delhi 
metallo-β-lactamase) described in 2009, the corresponding K. pneumoniae and E. coli isolates 
being from a Swedish patient of Indian origin hospitalized in Örebro, Sweden, after a hospital 
stay in New Delhi [62,63]. NDM-1 shares very little identity with other MBLs, the most 
similar being VIM-1/VIM-2 with only 32.4% amino acid identity. NDM-1 efficiently 
hydrolyses a broad range of β-lactams including penicillins, cephalosporins and carbapenems, 
just sparing monobactams such as aztreonam [62]. Since the first description of NDM-1, eight 
variants of this enzyme have been published (NDM-1 to -8) and twelve have been assigned 
(http://www.lahey.org), most of them originated from Asia [64-66]. Compared to NDM-1, the 
NDM-4, NDM-5 and NDM-7 variants possess increased activity towards carbapenems [67-
70]. A detailed analysis of the resistance patterns show their systematic association with other 
antibiotic resistance determinants such as plasmid-mediated AmpC cephalosporinases, 
11
ht
tp
://
do
c.
re
ro
.c
h
p
clavulanic-acid inhibited expanded-spectrum ß-lactamases (ESBLs), other types of 
carbapenemases (OXA-48-, VIM-, KPC-types),  broad spectrum resistance to 
aminoglycosides (16S RNA methylases), to quinolones (Qnr), to macrolides (esterases), to 
rifampicin (rifampicin-modifying enzymes), to chloramphenicol and to sulfamethoxazole 
[71,72]. Consequently, many of the NDM-1 producers remain susceptible only to colistin, 
fosfomycin and tigecycline [73]. 
 
The main identified reservoir of NDM-producing Enterobacteriaceae is the Indian 
subcontinent (Pakistan, India, Sri Lanka) [63]. Spread of NDM producers has been not only 
extensively identified among patients from the Indian subcontinent but also from the soil 
[74,75]. Therefore, it is likely that there the environment is already heavily contaminated by 
NDM producers. The prevalence of carriage is estimated at 5 to 15 % in that part of the world 
[76,77]. A significant spread of NDM producers has been identified also in the Great Britain 
with tight relationships with India and Pakistan [65]. Subsequently, NDM producers in 
Enterobacteriaceae have been reported almost worldwide including many countries in Asia, 
Africa, Australia, America, and Europe [78]. NDM producers are now on the top list of 
carbapenemase producers in European countries such as in the UK and in France [63,65]. 
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Another particularly important source of NDM producers (or established secondary 
reservoirs) is constituted by the Balkan states [79,80], the Arabic peninsula [81,82] and the 
North African countries [64]. The impact of intercontinental travels as a source of spread of 
NDM producers has been extensively reported. NDM producers are heavily identified in 
countries where many Indian and Pakistani live such as Canada, the USA, Great Britain, 
Ireland, South Africa, Saudi Arabia, Gulf countries, Australia etc... Noteworthy, the 
identification of NDM producers is not always associated with an Indian subcontinent origin, 
sustaining the hypothesis of established secondary reservoirs [83-87]. 
 
All types of NDM-producing enterobacterial species have been found involved in 
infections, but mostly K. pneumoniae and E. coli are sources of hospital and community 
acquired infections, respectively. The frequent identification of NDM-producing E. coli is of 
concern considering that E. coli is the first pathogen responsible for urinary tract infections, 
community-acquired infections, and diarrhea [88]. In fact, antibiotic resistance occurring in 
community settings are by definition very difficult to be contained and diarrhea is the source 
of a further spread of NDM producers in the environment at least in South East Asia. 
13
ht
tp
://
do
c.
re
ro
.c
h
p
 It may therefore be expected that outbreaks due mostly to NDM-producing K. 
pneumoniae will be increasingly reported worldwide and concomitantly, a slow but 
progressive increase in the prevalence rate of NDM-producing E. coli will be observed, 
mirrorring the spread of CTX-M producers we have observed in community setttings since 
the 2000's. Noteworthy, outbreaks with NDM-1-producing E. coli or E. cloacae have been 
reported in Bulgaria and Turkey, respectively [89,90]. It is however difficult to evaluate the 
time (years) it will take to obtain similar prevalence rates of NDM-producing E. coli 
comparable to those observed for CTX-M producers (15-70% depending of the countries). 
Long-term persistence of NDM producers in the human gut will contribute to further human-
to-human transfer [91], leading to some autochthonous cases in non endemic area as observed 
in France [92]. 
 
The carbapenem-hydrolysing class D ß-lactamases 
 Class D ß-lactamases, also named OXAs (for “oxacillinases”) include now more than 
400 enzymes, among which only some variants actually possess a carbapenemase activity 
[93]. With the exception of rare OXA-enzymes (such as OXA-163, see further), the 
carbapenem-hydrolysing class D ß-lactamases (CHDLs) do not hydrolyse (or very poorly) 
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expanded-spectrum cephalosporins. Noticeably, all CHDLs possess a weak carbapenemase 
activity which, by itself, does not confer high level resistance to carbapenems if not associated 
to other factors, such as permeability defects [94]. 
 
Although most of the CHDLs variants have been identified in Acinetobacter spp., 
OXA-48 and its derivatives are identified in Enterobacteriaceae [95]. The firstly identified 
OXA-48 producer was a K. pneumoniae isolate recovered in Turkey in 2003 [96]. Then, 
OXA-48 producers have been extensively reported from Turkey, being often the sources of 
nosocomial outbreaks [96-99]. OXA-48-producing isolates have now widely disseminated 
throughout European countries, and it is highly probable that one of the main reservoir, apart 
from Turkey, corresponds to North African countries [95]. Indeed most countries from the 
Mediterranean area frequently report the occurrence of the OXA-48-producing 
Enterobacteriaceae [95]. Hospital outbreaks involving OXA-48-producing K. pneumoniae, E. 
coli, and E. cloacae have been reported in many countries including France, Germany, 
Switzerland, Spain, the Netherlands, and UK [100-105]. One of the main  factors sustaining 
the successful spread of the blaOXA-48 gene among a variety of enterobacterial species 
corresponds to the high transfer efficiency of the plasmid on which blaOXA-48 is located [106]. 
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That self-conjugative plasmid, which is considered as epidemic, does not carry any additional 
resistance determinant, and conjugates at very high frequency from an to any enterobacterial 
species [107]. 
 
OXA-48-producing isolates have been reported in the Middle East, such as in 
Lebanon, Sultanate of Oman, Saudi Arabia, and Kuwait [108-114]. In Africa, they are mainly 
identified in the Northern countries (Morocco, Algeria, Tunisia, Egypt, Libya) [115-127], but 
occurrence of OXA-48 producers has also been identifeid in Senegal and South Africa 
[128,129]. 
 
The same OXA-48-producing K. pneumoniae of sequence type (ST) ST395 has been 
identified in Morocco, in France, and in the Netherlands, indicating a clonal dissemination in 
some instances [120]. Noteworthy, the recently identified occurrence of OXA-48 producers in 
Israel was demonstrated to be linked with medical tourism, that involved patients who had 
been transferred from Georgia or in Jordania [130]. Also noticeable is the fact that OXA-48 is 
still considered almost absent from the Americas, even though recent reports showed the 
emergence of OXA-48-producing K. pneumoniae in the US [30]. 
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A point-mutant derivative of OXA-48, namely OXA-181, sharing the same hydrolytic 
properties, has been identified in enterobacterial isolates from India or from patients with a 
link with the Indian subcontinent [131]. The genetic structure surrounding the blaOXA-181 gene 
was found to be distinct from that associated to blaOXA-48, thus indicating their respective 
current disseminations are not related to each other. The blaOXA-181 gene has been identified in 
different countries such as France, UK, Norway, Romania, Sultanate of Oman, Canada, 
Australia, New Zealand, Singapore, and Sri Lanka, and a link with India is quite 
systematically observed [95,129,133]. 
 
OXA-204 was recently identified from a series of K. pneumoniae isolates recovered 
from patients having a link with Algeria or Tunisia. OXA-204 exhibits two amino acid 
substitutions compared to OXA-48, and preliminary data indicate a substrate profile very 
similar to that of OXA-48 [134] (Figure 2). OXA-232 has been recently identified from K. 
pneumoniae isolates in France, from patients who had been transferred from Mauritius or 
India [134]. It exhibits five amino acid substitutions compared to OXA-48, but is just a point 
mutant derivative of OXA-181. OXA-232 possesses a weaker ability to hydrolyze 
carbapenems as compared to OXA-48, but was recently found co-associated to NDM-1 in a 
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carbapenem-resistant K. pneumoniae isolate in the US very recently from a patient who had 
been previously identified in India [135]. 
 
Finally, another OXA-48-like enzyme, namely OXA-163, has been recently identified 
from enterobacterial isolates recovered in Argentina [136]. OXA-163 differs from OXA-48 
by a single amino acid substitution together with a four amino-acid deletion [95,136]. 
Interestingly, although its carbapenemase activity is lower than that of OXA-48, its substrate 
profile includes broad-spectrum cephalosporins and its activity is partially inhibited by 
clavulanic acid, thus conferring to the corresponding enterobacterial recipient strains an 
resistance phenotype very similar to that of an ESBL producer. OXA-163 was originally 
identified from enterobacterial isolates (E. cloacae and K. pneumoniae) recovered in 
Argentina [136], and then in Egypt [137]. Other studies confirmed that OXA-163 producers 
were frequently identified in Argentina [30], and one single amino acid mutant (OXA-247) 
sharing the same hydrolytic properties was identified in that country [138].  
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Conclusion 
Although the spread of carbapenemases appear to be quite recent, the “big players” 
which are NDM, KPC, and OXA-48 are widely distributed worldwide nowadays. Important 
reservoirs have been identified, being the Indian subcontinent for NDM, the US, Israel, 
Greece and Italy for KPC, and Turkey and North Africa for OXA-48. The Indian subcontinent 
actually acts as a reservoir of all three types of carbapenemases, KPC, NDM and OXA-181. 
KPC producers are still mostly identified in nosocomial K. pneumoniae isolates. By contrast 
NDM and OXA-48 enzymes are extensively identified in nosocomial and community-
acquired K. pneumoniae and E. coli isolates, respectively. Interestingly KPC and NDM have 
been identified in unrelated Gram negatives species wheras OXA-48 remains identified only 
in enterobacterial species. However genetic analysis indicates that the OXA-48 gene will has 
a propensy to spread among enterobacterial species at a much higher rate than KPC and NDM 
genes. 
 
The identifed important reservoirs of those carbapenemase producers significantly act 
as sources for their dissemination worldwide. Indeed, it is extremely frequent to see that 
occurrence of a carbapenemase-producing isolate in a geographical area where there is no 
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endemicity or an epidemic situation linked to a patient who had a previous history of 
hospitalization or a travel in an endemic area. This indicates that a very early identification of 
carbapenemase producers at least in hospital settings may contribute to the limitation of their 
spread. Use of rapid diagnostic techniques is the key issue for their diagnosis followed by 
implementation of strict hygiene measure to limit their spread.   
 
Legends to Figures. 
Figure 1. Geographical distribution of KPC producers. 
Figure 2. Geographical distribution of NDM producers. 
Figure 3. Geographical distribution of OXA-48-like producers. 
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Figure 1. KPC producers
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Figure 2. NDM producers
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Unknown distribution of OXA-48 producers
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Endemicity of OXA-48 producers 
Figure 3. OXA-48 producers
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